APA (7th ed.) Citation

HA, K., AG, E., DL, V., PS, G., J, F., SF, S., . . . JS, H. (2002). A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: The Children's Cancer Group study (CCG-1962). Journal of pediatric hematology/oncology, 24(3), 175. https://doi.org/10.1097/00043426-200203000-00004

Chicago Style (17th ed.) Citation

HA, Kurre, Ettinger AG, Veenstra DL, Gaynon PS, Franklin J, Sencer SF, Reaman GH, Lange BJ, and Holcenberg JS. "A Pharmacoeconomic Analysis of Pegaspargase Versus Native Escherichia Coli L-asparaginase for the Treatment of Children with Standard-risk, Acute Lymphoblastic Leukemia: The Children's Cancer Group Study (CCG-1962)." Journal of Pediatric Hematology/oncology 24, no. 3 (2002): 175. https://doi.org/10.1097/00043426-200203000-00004.

MLA (9th ed.) Citation

HA, Kurre, et al. "A Pharmacoeconomic Analysis of Pegaspargase Versus Native Escherichia Coli L-asparaginase for the Treatment of Children with Standard-risk, Acute Lymphoblastic Leukemia: The Children's Cancer Group Study (CCG-1962)." Journal of Pediatric Hematology/oncology, vol. 24, no. 3, 2002, p. 175, https://doi.org/10.1097/00043426-200203000-00004.